Intellia Therapeutics, Inc. (NTLA) Expected to Announce Quarterly Sales of $5.83 Million
Wall Street analysts predict that Intellia Therapeutics, Inc. (NASDAQ:NTLA) will announce sales of $5.83 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $6.80 million. Intellia Therapeutics posted sales of $4.87 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 19.7%. The firm is scheduled to report its next earnings results on Tuesday, November 7th.
On average, analysts expect that Intellia Therapeutics will report full year sales of $5.83 million for the current fiscal year, with estimates ranging from $23.90 million to $35.70 million. For the next financial year, analysts expect that the firm will report sales of $40.00 million per share, with estimates ranging from $23.70 million to $56.30 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). The firm had revenue of $5.90 million during the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm’s revenue for the quarter was up 40.5% compared to the same quarter last year.
A number of equities analysts have issued reports on the company. Oppenheimer Holdings, Inc. assumed coverage on Intellia Therapeutics in a research report on Tuesday, July 18th. They issued a “market perform” rating on the stock. TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Chardan Capital lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a research report on Tuesday, August 29th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. Finally, Cann reaffirmed a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Intellia Therapeutics currently has an average rating of “Hold” and an average target price of $26.80.
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at approximately $101,000. IHT Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the 1st quarter valued at approximately $117,000. Bank of Montreal Can raised its position in shares of Intellia Therapeutics by 1,031.7% during the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after acquiring an additional 7,222 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Intellia Therapeutics by 117.7% during the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after acquiring an additional 4,351 shares in the last quarter. Finally, Nisa Investment Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at approximately $134,000. 46.52% of the stock is currently owned by institutional investors.
Intellia Therapeutics (NTLA) opened at 29.28 on Friday. The stock’s market capitalization is $1.06 billion. The firm has a 50-day moving average of $25.65 and a 200 day moving average of $25.65. Intellia Therapeutics has a 52 week low of $10.83 and a 52 week high of $31.90.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.